Abstract
BackgroundClinical data from our group supports that ovarian cancer (OC) patients respond better to immune checkpoint blockade (ICB) when targeting both PD-1 and CTLA4 compared to anti-PD-1 alone (33% v....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have